newsfilter
← Earnings
Earnings Releases·

Krystal Biotech — Third Quarter 2026 Earnings Summary

  • VYJUVEK net product revenue reached $127.3 million in Q3 2026, a 30% year-over-year increase, while total product revenue for the nine months ended September 30, 2026, rose to $362.9 million from $282.0 million in the prior period; however, net income for the quarter declined to $63.1 million from $79.4 million in the prior year quarter.
  • The company established full-year 2026 non-GAAP combined R&D and SG&A expense guidance at $155.0 million to $165.0 million and authorized a new share repurchase program of up to $400 million to be executed opportunistically over the next two years.
  • VYJUVEK pricing negotiations are complete in Germany and Italy with launches expected in Italy in early 2027, while the pipeline remains on track with registrational studies for KB407 and KB801 (EMERALD-1) initiating or progressing in 2027, despite slower-than-anticipated enrollment in the latter.
  • Interim data for KB707 showed a 31% objective response rate and 75% disease control rate in combination with pembrolizumab, and KB113 demonstrated lesion regression in over 80% of patients in a pilot study, with FDA discussions for advanced development underway.
Company
KRYSTAL BIOTECH INC
Sector
Healthcare
Industry
Biotechnology